Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Janux Therapeutics, Inc. (JANX)

Janux Therapeutics Q3 net loss narrows to $21.6 million; revenue slips to $9.3 million

Mixed Impact 3 of 5 earnings Written later

Janux Therapeutics reported third-quarter 2026 results for the period ended September 30, 2026. Collaboration revenue was $9.3 million, down from $10.0 million a year earlier, while the net loss narrowed to $21.6 million from $24.3 million, helped by lower research and development and general and administrative expenses. The company reported $945.7 million in cash, cash equivalents and short-term investments and said initial clinical data for JANX011 will be presented on November 9, 2026.

Key points

  • Q3 2026 collaboration revenue was $9.3 million, versus $10.0 million in Q3 2025; nine-month revenue was $23.3 million, versus $10.0 million.
  • Q3 2026 net loss was $21.6 million, or $0.34 per share, versus $24.3 million, or $0.39 per share, a year earlier.
  • Research and development expenses were $30.6 million, down from $34.6 million; general and administrative expenses were $10.0 million, down from $10.6 million.
  • Cash, cash equivalents and short-term investments were $945.7 million at September 30, 2026, versus $966.6 million at December 31, 2025.

The filing

CompanyJanux Therapeutics, Inc. (JANX)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:08 PM ET
Accession number0001193125-26-449790

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.